MedCity News December 11, 2025
The high dose of Eli Lilly’s retatrutide led to an average 28.7% loss in body weight measured at 68 weeks. These Phase 3 results are the first from the experimental obesity drug’s broad clinical trial program, which is on track to yield seven data readouts in the coming year.
An Eli Lilly drug candidate designed to hit three metabolic targets led patients to lose an average of 28.7% of their body weight in a late-stage clinical trial, setting a new high mark in the competitive chase to develop next-generation obesity medications.
But the preliminary Phase 3 results also show high rates of patients discontinuing treatment, which will be something to watch in the coming year for this weekly injectable medication,...
Today's Sponsors
Today's Sponsor